OPKO Health (NASDAQ:OPK) Upgraded at StockNews.com

StockNews.com upgraded shares of OPKO Health (NASDAQ:OPK) from a sell rating to a hold rating in a report issued on Wednesday morning.

OPK has been the topic of several other reports. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research report on Thursday, September 26th. Barrington Research restated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th.

OPKO Health Stock Down 3.1 %

NASDAQ:OPK opened at $1.56 on Wednesday. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health has a twelve month low of $0.85 and a twelve month high of $1.76. The company has a market cap of $1.06 billion, a PE ratio of -8.21 and a beta of 1.62. The company’s 50 day moving average is $1.54 and its two-hundred day moving average is $1.48.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost bought 125,000 shares of the stock in a transaction dated Friday, December 13th. The shares were acquired at an average cost of $1.59 per share, with a total value of $198,750.00. Following the purchase, the chief executive officer now directly owns 212,536,477 shares in the company, valued at $337,932,998.43. The trade was a 0.06 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have purchased a total of 1,304,255 shares of company stock valued at $2,024,605 over the last ninety days. Company insiders own 47.26% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

Several institutional investors and hedge funds have recently modified their holdings of the business. Rubric Capital Management LP boosted its position in OPKO Health by 800.0% during the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after purchasing an additional 39,486,490 shares in the last quarter. Y.D. More Investments Ltd acquired a new position in shares of OPKO Health during the 2nd quarter worth approximately $1,840,000. Assenagon Asset Management S.A. lifted its position in shares of OPKO Health by 142.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after buying an additional 876,272 shares in the last quarter. Clearline Capital LP acquired a new stake in OPKO Health in the 3rd quarter valued at $1,083,000. Finally, Squarepoint Ops LLC purchased a new stake in OPKO Health in the 2nd quarter worth $592,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.